Almstead Neil Gregory sold $4.1M of PTCT
Almstead Neil Gregory (CHIEF TECHNICAL OPS OFFICER) sold 46,774 shares of PTC THERAPEUTICS, INC. (PTCT) at an average of $87.52 ($85.28–$89.44, $4.09M total) across 8 trades over 2026-07-06 to 2026-07-07 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the officer’s open-market sale of 46,774 shares at a weighted average price of $87.5162, totaling $4,093,481.61, with holdings after the transaction of 60,299 shares.
Market read
Useful for tracking insider behavior in PTCT, but it does not provide new clinical, regulatory, or guidance information.
What to watch
Traders may want to compare this sale to prior insider transactions and whether holdings after the sale remain large enough to matter for signaling.
Background
The article is an SEC Form 4 insider transaction disclosure for PTC Therapeutics, filed 2026-07-08.
Ticker impact
PTCT insider Almstead Neil Gregory, Chief Technical Ops Officer, sold about $4.09M of shares via an open-market sale under a 10b5-1 plan.
Likely limited, short-lived sentiment impact; more relevant for monitoring insider activity than for fundamentals.
The filing is a Form 4 showing a multi-trade sale ($4.09M) by an officer, explicitly under a pre-arranged 10b5-1 plan, which typically reduces the signal of new negative information.
Market effects
Minimal sector read-through; this is company-specific insider activity without any disclosed regulatory, clinical, or product catalyst.
None indicated.
None indicated.
Counterpoint
Because the sale is under a 10b5-1 plan, it may reflect liquidity planning rather than a change in outlook, so the market reaction may be overstated.
Key entities
- issuerPTC THERAPEUTICS, INC.
Company whose insider transaction is disclosed on Form 4.
- insiderAlmstead Neil Gregory
Chief Technical Ops Officer who sold shares.
- trading mechanismRule 10b5-1 plan
Pre-arranged plan noted as Yes, which typically reduces interpretive signal.
